Primary Site >> Stomach Cancer
Gene >> FGFR2
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Ref: K-sam, an amplified gene in stomach cancer, is a member of the heparin-binding growth factor receptor genes. PMID: 2377625 |
Ref: DNA amplification in human gastric carcinomas. PMID: 8453595 |
Ref: A soluble form of K-sam/FGFR2 protein in the culture medium of human gastric cancer cells. PMID: 8060318 Ref: Preferential alternative splicing in cancer generates a K-sam messenger RNA with higher transforming activity. PMID: 8205545 Ref: Preferential expression of the third immunoglobulin-like domain of K-sam product provides keratinocyte growth factor-dependent growth in carcinoma cell lines. PMID: 8275490 |
Ref: A truncated K-sam product lacking the distal carboxyl-terminal portion provides a reduced level of autophosphorylation and greater resistance against induction of differentiation. PMID: 7791773 |
Ref: Immunohistochemical detection of K-sam protein in stomach cancer. PMID: 9816310 |
Ref: Deletion of the carboxyl-terminal exons of K-sam/FGFR2 by short homology-mediated recombination, generating preferential expression of specific messenger RNAs. PMID: 10626794 |
Ref: Up-regulation and co-expression of fibroblast growth factor receptors in human gastric cancer. PMID: 11003564 |
Ref: Mutations in fibroblast growth factor receptor 2 and fibroblast growth factor receptor 3 genes associated with human gastric and colorectal cancers. PMID: 11325814 |
Ref: FGFR2 and WDR11 are neighboring oncogene and tumor suppressor gene on human chromosome 10q26. PMID: 12684685 Ref: Recombination cluster around FGFR2-WDR11-HTPAPL locus on human chromosome 10q26. PMID: 12684693 Ref: MGC9753 gene, located within PPP1R1B-STARD3-ERBB2-GRB7 amplicon on human chromosome 17q12, encodes the seven-transmembrane receptor with extracellular six-cystein domain. PMID: 12739007 Ref: Alterations of chromosomal copy number during progression of diffuse-type gastric carcinomas: metaphase- and array-based comparative genomic hybridization analyses of multiple samples from individual tumours. PMID: 14595756 |
Ref: FIGC, a novel FGF-induced ubiquitin-protein ligase in gastric cancers. PMID: 15581609 |
Ref: Comparative genomics on Wnt8a and Wnt8b genes. PMID: 15754011 Ref: Allelic loss at 10q26 in osteosarcoma in the region of the BUB3 and FGFR2 genes. PMID: 15796961 Ref: Comparative genomics on Shisa orthologs. PMID: 15942696 Ref: Epithelial-mesenchymal transition in gastric cancer (Review). PMID: 16273224 |
Ref: Expression of keratinocyte growth factor receptor correlates with expansive growth and early stage of gastric cancer. PMID: 16391783 Ref: FGF signaling network in the gastrointestinal tract (review). PMID: 16773196 |
Ref: Aberrant hypermethylation of the FGFR2 gene in human gastric cancer cell lines. PMID: 17459342 Ref: AZD2171 shows potent antitumor activity against gastric cancer over-expressing fibroblast growth factor receptor 2/keratinocyte growth factor receptor. PMID: 17505008 Ref: Transforming properties of TC-1 in human breast cancer: interaction with FGFR2 and beta-catenin signaling pathways. PMID: 17520678 Ref: Aberrant fibroblast growth factor receptor signaling in bladder and other cancers. PMID: 17697126 |
Ref: FGFR2-amplified gastric cancer cell lines require FGFR2 and Erbb3 signaling for growth and survival. PMID: 18381441 Ref: Cancer genomics and genetics of FGFR2 (Review). PMID: 18636142 |
Ref: FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review). PMID: 19212647 Ref: FGFR2 abnormalities underlie a spectrum of bone, skin, and cancer pathologies. PMID: 19387476 |
Ref: Synergistic antitumor effects of FGFR2 inhibitor with 5-fluorouracil on scirrhous gastric carcinoma. PMID: 19621385 Ref: MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. PMID: 20145145 Ref: Gastric cancer cell line Hs746T harbors a splice site mutation of c-Met causing juxtamembrane domain deletion. PMID: 20331976 Ref: Monoclonal antibodies to fibroblast growth factor receptor 2 effectively inhibit growth of gastric tumor xenografts. PMID: 20670946 Ref: GP369, an FGFR2-IIIb-specific antibody, exhibits potent antitumor activity against human cancers driven by activated FGFR2 signaling. PMID: 20709759 Ref: Genetic alterations of FGF receptors: an emerging field in clinical cancer diagnostics and therapeutics. PMID: 20836672 |
Ref: New targeted therapies for gastric cancer. PMID: 21406037 Ref: A FGFR2 inhibitor, Ki23057, enhances the chemosensitivity of drug-resistant gastric cancer cells. PMID: 21482024 |
Ref: Three-gene predictor of clinical outcome for gastric cancer patients treated with chemotherapy. PMID: 21173787 Ref: Foretinib (GSK1363089), a multi-kinase inhibitor of MET and VEGFRs, inhibits growth of gastric cancer cell lines by blocking inter-receptor tyrosine kinase networks. PMID: 21655918 Ref: Integrated analysis of whole genome exon array and array-comparative genomic hybridization in gastric and colorectal cancer cells. PMID: 22034905 Ref: FGFR2 gene amplification and clinicopathological features in gastric cancer. PMID: 22240789 Ref: A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets. PMID: 22315472 Ref: Fibroblast growth factor receptor 2 gene amplification status and its clinicopathologic significance in gastric carcinoma. PMID: 22440694 Ref: Multidimensional identification of tissue biomarkers of gastric cancer. PMID: 22533479 Ref: Gastrointestinal adenocarcinomas of the esophagus, stomach, and colon exhibit distinct patterns of genome instability and oncogenesis. PMID: 22751462 Ref: [Mechanisms responsible for the progression of scirrhous gastric cancer]. PMID: 23198567 |
Ref: FGFR2 gene amplification in gastric cancer predicts sensitivity to the selective FGFR inhibitor AZD4547. PMID: 23493349 Ref: S49076 is a novel kinase inhibitor of MET, AXL, and FGFR with strong preclinical activity alone and in association with bevacizumab. PMID: 23804704 Ref: Towards the goal of personalized medicine in gastric cancer--time to move beyond HER2 inhibition. Part I: Targeting receptor tyrosine kinase gene amplification. PMID: 23819947 Ref: Towards the goal of personalized medicine in gastric cancer--time to move beyond HER2 inhibition. Part II: Targeting gene mutations and gene amplifications and the angiogenesis pathway. PMID: 23911227 Ref: [Developing FGFR inhibitors as potential anti-cancer agents]. PMID: 23926649 Ref: Fibroblast growth factor receptor 2: a therapeutic target in gastric cancer. PMID: 24134151 |
Ref: FGF receptors: cancer biology and therapeutics. PMID: 23696246 Ref: Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma. PMID: 24122810 Ref: FGFR2 amplification has prognostic significance in gastric cancer: results from a large international multicentre study. PMID: 24457912 Ref: Intratumoral heterogeneous amplification of ERBB2 and subclonal genetic diversity in gastric cancers revealed by multiple ligation-dependent probe amplification and fluorescence in situ hybridization. PMID: 24491355 Ref: HER2, MET and FGFR2 oncogenic driver alterations define distinct molecular segments for targeted therapies in gastric carcinoma. PMID: 24518603 Ref: Saracatinib impairs the peritoneal dissemination of diffuse-type gastric carcinoma cells resistant to Met and fibroblast growth factor receptor inhibitors. PMID: 24612061 Ref: Targeting receptor tyrosine kinases in gastric cancer. PMID: 24782606 Ref: Whole genome gene copy number profiling of gastric cancer identifies PAK1 and KRAS gene amplification as therapy targets. PMID: 24935174 Ref: Prognostic significance of the co-overexpression of fibroblast growth factor receptors 1, 2 and 4 in gastric cancer. PMID: 24940486 Ref: FGFR2 is amplified in the NCI-H716 colorectal cancer cell line and is required for growth and survival. PMID: 24968263 Ref: Overexpression of miR-17 in gastric cancer is correlated with proliferation-associated oncogene amplification. PMID: 25047501 Ref: Mutually exclusive FGFR2, HER2, and KRAS gene amplifications in gastric cancer revealed by multicolour FISH. PMID: 25086186 Ref: One patient, two lesions, two oncogenic drivers of gastric cancer. PMID: 25222187 Ref: Pazopanib, a novel multitargeted kinase inhibitor, shows potent in vitro antitumor activity in gastric cancer cell lines with FGFR2 amplification. PMID: 25249557 Ref: Metastatic tumor evolution and organoid modeling implicate TGFBR2 as a cancer driver in diffuse gastric cancer. PMID: 25315765 Ref: Twist1 correlates with poor differentiation and progression in gastric adenocarcinoma via elevation of FGFR2 expression. PMID: 25561797 |
Ref: Expression profiles of HER2, EGFR, MET and FGFR2 in a large cohort of patients with gastric adenocarcinoma. PMID: 24626858 Ref: Identification of EGFR expression status association with metastatic lymph node density (ND) by expression microarray analysis of advanced gastric cancer. PMID: 25154973 Ref: The therapeutic potential of a novel non-ATP-competitive fibroblast growth factor receptor 1 inhibitor on gastric cancer. PMID: 25521558 Ref: Multiple receptor tyrosine kinase activation attenuates therapeutic efficacy of the fibroblast growth factor receptor 2 inhibitor AZD4547 in FGFR2 amplified gastric cancer. PMID: 25576915 Ref: Semi-comprehensive analysis of gene amplification in gastric cancers using multiplex ligation-dependent probe amplification and fluorescence in situ hybridization. PMID: 25743022 Ref: Prospective comprehensive genomic profiling of advanced gastric carcinoma cases reveals frequent clinically relevant genomic alterations and new routes for targeted therapies. PMID: 25882375 Ref: FGFR2 Assessment in Gastric Cancer Using Quantitative Real-Time Polymerase Chain Reaction, Fluorescent In Situ Hybridization, and Immunohistochemistry. PMID: 25972329 Ref: Therapeutic targeting of fibroblast growth factor receptors in gastric cancer. PMID: 26000013 Ref: Patient-Derived Gastric Carcinoma Xenograft Mouse Models Faithfully Represent Human Tumor Molecular Diversity. PMID: 26217940 Ref: Amplification of FGFR2 Gene in Patients with Advanced Gastric Cancer Receiving Chemotherapy: Prevalence and Prognostic Significance. PMID: 26254407 Ref: Expression of Fibroblast Growth Factor 10 Is Correlated with Poor Prognosis in Gastric Adenocarcinoma. PMID: 26268776 Ref: Diffuse-type gastric cancer cells switch their driver pathways from FGFR2 signaling to SDF1/CXCR4 axis in hypoxic tumor microenvironments. PMID: 26385890 Ref: Evaluation of Fibroblast Growth Factor Receptor 2 Expression, Heterogeneity and Clinical Significance in Gastric Cancer. PMID: 26516773 Ref: Identification of short-form RON as a novel intrinsic resistance mechanism for anti-MET therapy in MET-positive gastric cancer. PMID: 26528757 Ref: Intra-Tumoral Heterogeneity of HER2, FGFR2, cMET and ATM in Gastric Cancer: Optimizing Personalized Healthcare through Innovative Pathological and Statistical Analysis. PMID: 26587992 Ref: Overexpression of FGFR2 contributes to inherent resistance to MET inhibitors in MET-amplified patient-derived gastric cancer xenografts. PMID: 26622787 |
Ref: Epithelial-mesenchymal transition confers resistance to selective FGFR inhibitors in SNU-16 gastric cancer cells. PMID: 25407459 Ref: Comprehensive analyses using next-generation sequencing and immunohistochemistry enable precise treatment in advanced gastric cancer. PMID: 26489445 Ref: Molecular Modeling, de novo Design and Synthesis of a Novel, Extracellular Binding Fibroblast Growth Factor Receptor 2 Inhibitor Alofanib (RPT835). PMID: 26732115 Ref: Targeted therapies in gastric cancer treatment: where we are and where we are going. PMID: 26873643 Ref: Value of FGFR2 expression for advanced gastric cancer patients receiving pazopanib plus CapeOX (capecitabine and oxaliplatin). PMID: 26983912 Ref: Prognostic impact of KRAS mutant type and MET amplification in metastatic and recurrent gastric cancer patients treated with first-line S-1 plus cisplatin chemotherapy. PMID: 27014419 Ref: Genomic Alterations and Targeted Therapy in Gastric and Esophageal Adenocarcinoma. PMID: 27041412 Ref: A reciprocal regulatory circuit between CD44 and FGFR2 via c-myc controls gastric cancer cell growth. PMID: 27107424 Ref: Prognosis of Pregnancy-Associated Gastric Cancer: An Age-, Sex-, and Stage-Matched Case-Control Study. PMID: 27114414 Ref: High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical Trial. PMID: 27179038 Ref: M-COPA, a Golgi Disruptor, Inhibits Cell Surface Expression of MET Protein and Exhibits Antitumor Activity against MET-Addicted Gastric Cancers. PMID: 27197184 Ref: FGFR2 in gastric cancer: protein overexpression predicts gene amplification and high H-index predicts poor survival. PMID: 27230412 Ref: FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review). PMID: 27245147 Ref: Importance of the type I insulin-like growth factor receptor in HER2, FGFR2 and MET-unamplified gastric cancer with and without Ras pathway activation. PMID: 27437872 Ref: The coexpression and prognostic significance of c-MET, fibroblast growth factor receptor 2, and human epidermal growth factor receptor 2 in resected gastric cancer: a retrospective study. PMID: 27729801 Ref: Therapeutics Targeting FGF Signaling Network in Human Diseases. PMID: 27992319 |
Ref: Prognostic impact of fibroblast growth factor receptor 2 gene amplification in patients receiving fluoropyrimidine and platinum chemotherapy for metastatic and locally advanced unresectable gastric cancers. PMID: 27802183 Ref: Sprouty2 correlates with favorable prognosis of gastric adenocarcinoma via suppressing FGFR2-induced ERK phosphorylation and cancer progression. PMID: 28002800 Ref: Different clinical significance of FGFR1-4 expression between diffuse-type and intestinal-type gastric cancer. PMID: 28056982 Ref: Acquired resistance to LY2874455 in FGFR2-amplified gastric cancer through an emergence of novel FGFR2-ACSL5 fusion. PMID: 28122360 Ref: Molecular heterogeneity in the novel fusion gene APIP-FGFR2: Diversity of genomic breakpoints in gastric cancer with high-level amplifications at 11p13 and 10q26. PMID: 28123544 Ref: Establishment of patient-derived gastric cancer xenografts: a useful tool for preclinical evaluation of targeted therapies involving alterations in HER-2, MET and FGFR2 signaling pathways. PMID: 28292264 Ref: Targeting the fibroblast growth factor receptor 2 in gastric cancer: promise or pitfall? PMID: 28327938 Ref: FGF7/FGFR2 signal promotes invasion and migration in human gastric cancer through upregulation of thrombospondin-1. PMID: 28339036 Ref: Circulating tumor DNA profiling by next generation sequencing reveals heterogeneity of crizotinib resistance mechanisms in a gastric cancer patient with MET amplification. PMID: 28460431 Ref: Antitumor Effect of AZD4547 in a Fibroblast Growth Factor Receptor 2-Amplified Gastric Cancer Patient-Derived Cell Model. PMID: 28501555 Ref: Prognostic role of fibroblast growth factor receptor 2 in human solid tumors: A systematic review and meta-analysis. PMID: 28618942 Ref: Linked read sequencing resolves complex genomic rearrangements in gastric cancer metastases. PMID: 28629429 Ref: FGFR2 amplification in colorectal adenocarcinoma. PMID: 28835367 Ref: Fibroblast Growth Factor Receptor 2 Signaling in Breast Cancer. PMID: 29104507 Ref: Identification and validation of FGFR2 peptide for detection of early Barrett's neoplasia. PMID: 29152066 Ref: A randomized, open-label study of the efficacy and safety of AZD4547 monotherapy versus paclitaxel for the treatment of advanced gastric adenocarcinoma with FGFR2 polysomy or gene amplification. PMID: 29177434 |
Ref: Frequent Coamplification of Receptor Tyrosine Kinase and Downstream Signaling Genes in Japanese Primary Gastric Cancer and Conversion in Matched Lymph Node Metastasis. PMID: 27779515 Ref: In situ analysis of FGFR2 mRNA and comparison with FGFR2 gene copy number by dual-color in situ hybridization in a large cohort of gastric cancer patients. PMID: 28852882 Ref: SOMCL-085, a novel multi-targeted FGFR inhibitor, displays potent anticancer activity in FGFR-addicted human cancer models. PMID: 28905937 Ref: Acquired Resistance to FGFR Inhibitor in Diffuse-Type Gastric Cancer through an AKT-Independent PKC-Mediated Phosphorylation of GSK3beta. PMID: 28978722 Ref: Triple Angiokinase Inhibitor Nintedanib Directly Inhibits Tumor Cell Growth and Induces Tumor Shrinkage via Blocking Oncogenic Receptor Tyrosine Kinases. PMID: 29263244 Ref: Targeting the fibroblast growth factor receptor 2 in gastric cancer: promise or pitfall? PMID: 29300805 Ref: Impact of genomic alterations on lapatinib treatment outcome and cell-free genomic landscape during HER2 therapy in HER2+ gastric cancer patients. PMID: 29409051 Ref: Prognostic relevance of FGFR2 expression in stage II/III gastric cancer with curative resection and S-1 chemotherapy. PMID: 29434882 Ref: TM2D3 rs675436 or FGFR2 rs755793 polymorphisms and susceptibility to Epstein-Barr virus-associated tumors in Chinese Han population. PMID: 29446487 Ref: miR494 inhibits cancerinitiating cell phenotypes and reverses resistance to lapatinib by downregulating FGFR2 in HER2positive gastric cancer. PMID: 29786108 Ref: The significance of scirrhous gastric cancer cell lines: the molecular characterization using cell lines and mouse models. PMID: 29876827 Ref: DEAD-Box Protein RNA-Helicase DDX6 Regulates the Expression of HER2 and FGFR2 at the Post-Transcriptional Step in Gastric Cancer Cells. PMID: 29987267 Ref: Upregulation of EphB3 in gastric cancer with acquired resistance to a FGFR inhibitor. PMID: 30044964 Ref: Acquired JHDM1D-BRAF fusion confers resistance to FGFR inhibition in FGFR2- amplified gastric cancer. PMID: 30045926 Ref: Somatic mutational profiles of stage II and III gastric cancer according to tumor microenvironment immune type. PMID: 30239046 Ref: FGFR2 Promotes Gastric Cancer Progression by Inhibiting the Expression of Thrombospondin4 via PI3K-Akt-Mtor Pathway. PMID: 30355943 |